| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Our integration with a world-renowned medical center equips us with patient experience that supports development of disease-specific, algorithmic-based testing approaches that provide faster answers for each patient. Whether screening patients or monitoring therapeutic management, our evaluations cover the full-spectrum of gastroenterology testing.
“Sometimes we can identify a different reason for patients’ symptoms that requires a different treatment course, and that can improve their outcome. When you can actually make a big difference like that, it’s always a test to be proud of.”
Ann Moyer, M.D., Ph.D., co-director of the Personalized Genomics Laboratory
Our difference
The latest
Mayo Clinic Laboratories has introduced a revolutionary diagnostic test for bile acid malabsorption, a significant contributor to chronic diarrhea. Developed by Dr. Michael Camilleri and Dr. Leslie Donato, this new bile acid malabsorption panel simplifies diagnosis and improves patient care by eliminating the need for special diets or prolonged stool collection. The test's effectiveness has been validated internationally, offering new treatment avenues for patients. Discover how this innovative test is transforming clinical practice and enhancing patient outcomes.
This week’s Research Roundup highlights the development of a microscopic colitis disease activity index.
In a recent issue of Mayo Clinic's Digestive Diseases, Michael Camilleri, M.D., a gastroenterologist at Mayo Clinic, and Leslie Donato, Ph.D., Co-Director for Cardiovascular Laboratory Medicine, Hospital Clinical Laboratory, and Point of Care Testing at Mayo Clinic, discuss bile acid malabsorption testing in clinical practice.
In this month’s “Hot Topic,” Melissa Snyder, Ph.D., will review the diagnostic testing algorithms for celiac disease and highlight the advantages and limitations of certain tests, including serology and genetic assays.
Leslie Donato, Ph.D., Consultant in Cardiovascular Laboratory Medicine and Clinical Core Laboratory at Mayo Clinic, recently authored an article in "Medical Lab Management" on new laboratory testing options to evaluate irritable bowel syndrome with diarrhea (IBS-D) patients.
This week’s Research Roundup highlights prehospital transfusion for gastrointestinal bleeding.
Ann Moyer, M.D., Ph.D., discusses an additional gene, NUDT15, which is important in the prediction of thiopurine-related toxicity This gene has been added to our TPMT genotyping assay available through Mayo Medical Laboratories.
This week’s Research Roundup highlights autologous mesenchymal stem cells, applied in a bioabsorbable matrix, for treatment of perianal fistulas in patients with Crohn's disease.
An algorithm is a step-by-step procedure to guide clinicians and laboratorians in appropriate laboratory test ordering.
This week’s Research Roundup highlights autologous mesenchymal stem cells, applied in a bioabsorbable matrix, for treatment of perianal fistulas in patients with Crohn's disease.
Detection of individuals with low thiopurine methyltransferase (TPMT) activity who are at risk for excessive myelosuppression or severe hematopoietic toxicity when taking thiopurine drugs.
Mayo Clinic has completed validation of its existing Infliximab Quantitation with Reflex to Antibodies to Infliximab, Serum test for the new biosimilar drug Inflectra. Clients[...]
The differential diagnosis for inflammatory bowel disease (IBD) includes irritable bowel syndrome (IBS). While the clinical presentation is similar, IBD is an inflammatory disease, while IBS is a noninflammatory disease. View this "Hot Topic" to learn about testing for IBD and IBS.